Trojan horses at leptomeningeal cellular gates: Antibody–drug conjugates deliver cytotoxic payloads
Abstract
No abstract availableKeywords
Funding Information
- Jackson Laboratory
- National Institutes of Health
- Foundation for the National Institutes of Health
- National Cancer Institute
- Boehringer Ingelheim
- Merck
This publication has 11 references indexed in Scilit:
- Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategiesSeminars in Cancer Biology, 2025
- Survival outcomes among patients with breast cancer and leptomeningeal diseaseScientific Reports, 2025
- Ag(e)nostic precision oncology therapy approvals across the yearsTrends in Cancer, 2025
- The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosisMed, 2024
- Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?Critical Reviews in Oncology/Hematology, 2024
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialJournal of Clinical Oncology, 2024
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyNature Medicine, 2019
- Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain MetastasesJournal of Thoracic Oncology, 2018
- Targeted Therapy in Brain Metastases: Ready for Primetime?American Society of Clinical Oncology Educational Book, 2016
- Molecular Profiling and the Reclassification of Cancer: Divide and ConquerAmerican Society of Clinical Oncology Educational Book, 2013